Pfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor function for boys with Duchenne muscular dystrophy (DMD). The late-stage miss comes a little more than a ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

The MLX81300 is the first member of a family of LIN motor drivers. For positioning applications the MLX81300 can control 3 phase steppers with low noise microstepping, as well as DC motors.

A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy (SMA) has missed its primary endpoint. The biotech plans to talk to the FDA about the next steps in SMA and is stepping up ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta–selective agonist in development for ...